Senior Research Associate/Associate Scientist – In vivo Biology

Dyne Therapeutics

Role: Dyne is seeking a talented and highly motivated Senior Research Associate/Associate Scientist in the in vivo biology group to support our drug discovery programs. This member will collaborate closely with cross-functional groups, execute established biomarker assays using a variety of readout technologies.

The successful candidate will be ambitious, motivated, an energetic self-starter, and enjoy working in a fast-paced environment.  We offer a competitive salary with benefits and opportunities for learning and advancement in an exciting start-up environment.

Primary Responsibilities Include:

  • Execute research plans for in vivo studies.
  • Analyze data and communicate findings to team members and management.
  • Contribute to critical discussion of experimental design and assay development.

Education and Skills Requirements:

  • BS/MS or equivalent in a biological discipline and 1-3 years of hands-on academic/ industry experience.
  • Experience required in one or more of the following:
    • Oligonucleotide therapeutics
    • Antibody therapeutics
    • Muscle biology
  • Experience with molecular biology techniques including, but not limited to:
    • Nucleic acid isolation extraction for gene expression analysis.
    • Protein isolation, performing Western blots and ELISA.
    • Familiarity with histological protocols (tissue-fixation, embedding, sectioning, staining, IF, IHC) is beneficial.
  • Experience with handling in vivo samples is desirable.
  • Have excellent organizational skills, be detailed-oriented, and the ability to support others in a faced-paced environment.
  • Ability to effectively communicate ideas and document research.
  • Experienced in software applications (Prism, Excel, PowerPoint).
Waltham, MA, United States
Employment Type
Full Time
Job Location
On Site
Valid Through
31 Jul 2020
Posted On
10 Jul 2020

Organization Information

Dyne Therapeutics

Dyne Therapeutics is pioneering life-transforming therapies for patients with serious muscle diseases. The company’s FORCE™ platform delivers oligonucleotides and other molecules to skeletal, cardiac and smooth muscle with unprecedented precision to restore muscle health. Dyne is advancing treatments for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass.

WMS Twitter Feed
WMS Facebook Feed